GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CytoDyn Inc (STU:296) » Definitions » Cash Flow for Dividends

CytoDyn (STU:296) Cash Flow for Dividends : €0.00 Mil (TTM As of Feb. 2025)


View and export this data going back to 2016. Start your Free Trial

What is CytoDyn Cash Flow for Dividends?

CytoDyn's cash flow for dividends for the three months ended in Feb. 2025 was €0.00 Mil. Its cash flow for dividends for the trailing twelve months (TTM) ended in Feb. 2025 was €0.00 Mil.

Note: A negative number here means the payment of dividends. When pays more dividends, the absolute value gets bigger.


CytoDyn Cash Flow for Dividends Historical Data

The historical data trend for CytoDyn's Cash Flow for Dividends can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CytoDyn Cash Flow for Dividends Chart

CytoDyn Annual Data
Trend May15 May16 May17 May18 May19 May20 May21 May22 May23 May24
Cash Flow for Dividends
Get a 7-Day Free Trial Premium Member Only Premium Member Only - -0.20 - - -

CytoDyn Quarterly Data
May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25
Cash Flow for Dividends Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

CytoDyn Cash Flow for Dividends Calculation

Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Cash Flow for Dividends for the trailing twelve months (TTM) ended in Feb. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


CytoDyn Cash Flow for Dividends Related Terms

Thank you for viewing the detailed overview of CytoDyn's Cash Flow for Dividends provided by GuruFocus.com. Please click on the following links to see related term pages.


CytoDyn Business Description

Traded in Other Exchanges
Address
1111 Main Street, Suite 660, Vancouver, WA, USA, 98660
CytoDyn Inc is a USA-based clinical-stage biotechnology company that focuses on the clinical development and potential commercialization of humanized monoclonal antibodies to treat Human Immunodeficiency Virus (HIV) infection. The product candidate is PRO 140, which is a class of HIV therapy called entry inhibitors that block HIV from entering into and infecting certain cells. The company emphasizes exploring opportunities for clinical applications for PRO 140 involving the CCR5 (C-C chemokine receptor type 5) receptor, other than HIV-related treatments, such as inflammatory conditions, autoimmune diseases, and cancer.

CytoDyn Headlines

No Headlines